Document is current
Any future updates will be listed below
-
Authors
de Leon, Jose https://orcid.org/0000-0002-7756-2314
Schoretsanitis, Georgios https://orcid.org/0000-0002-3851-4117
Ruan, Can-Jun https://orcid.org/0000-0002-1625-7367
De las Cuevas, Carlos https://orcid.org/0000-0001-5742-905X
Kane, John M. https://orcid.org/0000-0002-2628-9442
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
- License Information
-
More Information
Article History
First Online: 8 April 2022
Declarations
:
: In the last 3 years, GS has served as a consultant for HLS Therapeutics; JMK has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group; and CUC has been a consultant and/or advisor to or has received honoraria from: AbbVie, Acadia, Alkermes, Allergan, Angelini, Aristo, Axsome, Cardio Diagnostics, Compass, Damitsa, Gedeon Richter, Hikma, IntraCellular Therapies, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Medscape, Merck, Mitsubishi Tanabe Pharma, Mindpax, Mylan, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Relmada, Reviva, Rovi, Seqirus, Servier, SK Life Science, Sumitomo Dainippon, Sunovion, Supernus, Takeda, Teva, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on Data Safety Monitoring Boards for Lundbeck, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, LB Pharma and Mindpax. In the last 3 years, C-JR, CDlC and JdL report no conflicts of interest.
Free to read: This content has been made available to all.
